EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)

Lijuan Zeng iD, Jamie Perin, Alden L Gross, David Shade, Krista L Lanctôt iD, Alan J Lerner, Jacobo E Mintzer, Olga Brawman-Mintzer, Prasad R Padala, Christopher H van Dyck, Anton P Porsteinsson, Suzanne Craft und 3 weitere

International Journal of Geriatric Psychiatry · 2024

DOI: 10.1002/gps.6108 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Geriatric Psychiatry, 2024. Verfasst von Lijuan Zeng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Methylphenidate, Apathy, Central Nervous System Stimulants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NCATS NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To examine clinically important adverse events (AEs) associated with methylphenidate (MPH) treatment of apathy in Alzheimer's Disease (AD) versus placebo, including weight loss, vital signs, falls, and insomnia.

Methods

The Apathy in Dementia Methylphenidate Trial 2 (ADMET2) trial was a multicenter randomized, placebo‐controlled trial of MPH to treat apathy in individuals with apathy and AD. Participants in ADMET2 had vital signs and weight measured at monthly visits through 6 months. AEs, including insomnia, falls, and cardiovascular events, were reported at every visit by participants and families using a symptom checklist.

Results

The study included 98 participants in the MPH group and 101 in the placebo group. Participants in the MPH group experienced greater weight loss on average than the placebo through the 6‐month follow‐up, with a difference in change between MPH and placebo of 2.8 lb (95% confidence interval, CI: 0.7, 4.9 lb). No treatment group differences in change during the trial were found in systolic and diastolic blood pressure. More participants in the MPH group reported falls during the follow‐up, 10 versus 6 in MPH and placebo groups, respectively. No differences in post‐baseline insomnia were observed between the treatment groups. No participants reported instances of myocardial infarction, congestive heart failure, arrhythmia, stroke, or cardiomyopathy throughout the study period.

Conclusions

MPH use in AD patients for treating apathy is relatively safe, particularly notable given the many medical comorbidities in this population. There was a statistically significant but modest weight loss associated with MPH use, and clinicians are thus advised to monitor weight during MPH treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseMethylphenidateApathyCentral Nervous System StimulantsWeight LossAccidental FallsHumansFemaleMaleAgedAged, 80 and overDouble-Blind MethodSleep Initiation and Maintenance Disorders

Stichwörter der Autor:innen

Alzheimer's diseaseadverse eventsapathymethylphenidateweight loss

Substanzen

MethylphenidateCentral Nervous System Stimulants

Autor:innen und Institutionen

  • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Global Disease Epidemiology and Control, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
  • Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, South Carolina, USA.

ORCID-Profile: Lijuan Zeng, Krista L Lanctôt

Förderung

  • NIA NIH HHS
  • NCATS NIH HHS
  • National Institute on Aging

Zitieren

APA

Zeng, L., Perin, J., Gross, A. L., Shade, D., Lanctôt, K. L., Lerner, A. J., Mintzer, J. E., Brawman-Mintzer, O., Padala, P. R., van Dyck, C. H., Porsteinsson, A. P., Craft, S., Levey, A., Herrmann, N., & Rosenberg, P. B. (2024). Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial). International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.6108

Vancouver

Zeng L, Perin J, Gross AL, Shade D, Lanctôt KL, Lerner AJ, et al. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial). International Journal of Geriatric Psychiatry. 2024. doi:10.1002/gps.6108

BibTeX
@article{Zeng2024,
  author = {Zeng, Lijuan and Perin, Jamie and Gross, Alden L and Shade, David and Lanctôt, Krista L and Lerner, Alan J and Mintzer, Jacobo E and Brawman-Mintzer, Olga and Padala, Prasad R and van Dyck, Christopher H and Porsteinsson, Anton P and Craft, Suzanne and Levey, Allan and Herrmann, Nathan and Rosenberg, Paul B},
  title = {Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)},
  journal = {International Journal of Geriatric Psychiatry},
  year = {2024},
  doi = {10.1002/gps.6108}
}
Kostenlos starten →